Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

91.96EUR
9:30am EDT
Change (% chg)

€1.32 (+1.46%)
Prev Close
€90.64
Open
€91.16
Day's High
€92.00
Day's Low
€90.51
Volume
1,216,647
Avg. Vol
3,014,183
52-wk High
€99.23
52-wk Low
€69.58

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.62
Market Cap(Mil.): €119,157.20
Shares Outstanding(Mil.): 1,314.63
Dividend: 2.85
Yield (%): 3.14

Financials

  SASY.PA Industry Sector
P/E (TTM): 27.97 37.06 39.11
EPS (TTM): 3.24 -- --
ROI: -- 16.25 15.56
ROE: -- 17.01 16.57
Search Stocks

BRIEF-NeuroVive teams up with Sanofi for Ciclomulsion launch in South Korea

* NeuroVive Asia signs collaboration agreement with Sanofi for the development and commercialization of ciclomulsion in South Korea

26 May 2015

Amgen first to win EU backing for new kind of cholesterol drug

- Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

22 May 2015

Amgen first to win EU backing for new kind of cholesterol drug

May 22 - Amgen Inc's closely watched new cholesterol drug, Repatha, has been recommended for approval in Europe, putting the U.S. drugmaker ahead in a race with rival Sanofi SA.

22 May 2015

Amgen cholesterol drug could get EU green light this week

LONDON - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

19 May 2015

Amgen cholesterol drug could get EU green light this week

LONDON, May 19 - Amgen's new cholesterol drug Repatha could be recommended for approval in Europe as early as this week, putting it ahead in a race with a rival product from Sanofi.

19 May 2015

BRIEF-Evotec raises 2015 revenue guidance on Sanofi alliance

* Group EBITDA before contingent considerations at eur (0.3) m significantly improved compared to same period of previous year (2014: eur (1.3) m)

12 May 2015

UPDATE 1-Hedge fund firm Man Group feels investor backlash on pay

* Follows rebellions at companies from Sanofi to Barrick Gold (Adds detail from statement, quote from company)

08 May 2015

UPDATE 1-Sanofi rebels make mark in AGM vote on CEO pay

* Large shareholder minority votes against the pay packages (Adds detail on packages)

04 May 2015

Sanofi rebels make mark in AGM vote on CEO pay

PARIS, May 4 - Shareholders in drugs group Sanofi , which sacked its chief executive last year and appointed a new one in February, approved millions of euros in payments to both men on Monday despite a substantial rebellion by activist investors.

04 May 2015

RPT-Sanofi faces AGM row over cost of firing and hiring CEOs

PARIS, April 30 - Drugs group Sanofi, which sacked its chief executive last year and appointed a new one in February, has appealed for shareholder loyalty as it seeks to head off a potential rebellion over millions of euros in payments to both men.

01 May 2015

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$1,000.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks